Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNano Genomics Inc (BNGO) vs TeraWulf Inc (WULF) Price & Performance

BioNano Genomics IncTrade
TeraWulf IncTrade

Price performance (Past 24H)

Key statistics

BioNano Genomics Inc vs TeraWulf Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while TeraWulf Inc trades at $17.19 (market cap $8.35B). The key difference: TeraWulf Inc is far larger — about 611.3× BioNano Genomics Inc's market cap, and TeraWulf Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.

BNGOWULF
Market Cap
$13.66M$8.35B
Sector
HealthTechnology
52-Week High
$4.92$28.98
52-Week Low
$1.06$5.24
Enterprise Value
$16.26M$10.97B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNano Genomics Inc

BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.

The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.

TeraWulf Inc

WULF trades at $17.19, up 6.11% today amid a broader neocloud sector rally. The stock shows bearish technical signals with negative earnings trends, posting significant losses in recent quarters. Despite strong analyst consensus (14 buy ratings, 0 hold/sell), fundamental metrics reveal challenges with a P/S of 43.81, P/B of 56.71, and deeply negative profit margins. Recent news highlights the company's pivot to high-performance computing with a major Anthropic deal and 102 MW of operational capacity.

The outlook remains speculative with high execution risks and substantial capital requirements. While analyst price targets average $38.00 (121% upside potential), investors face volatility from ongoing losses, construction cost pressures, and regulatory exposure to New York's data-center moratorium. The stock's performance will depend on successful HPC expansion and profitability improvements.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO

About TeraWulf Inc

TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.

Read more on WULF